welcome to oneEDSvoice
- a positively charged Ehlers Danlos Syndrome community.- join today!
- login
Acer Therapeutics Obtains Exclusive License to Celiprolol Pivotal Clinical Data from AP-HP
“We have studied celiprolol for nearly two decades in vEDS patients and this is the only drug ever to demonstrate a clinical benefit in a randomized, controlled clinical study,” said Pierre Boutouyrie M.D., Ph.D., co-director of the clinical pharmacology service at the Georges-Pompidou European Hospital AP-HP and Principal Investigator for the celiprolol study. “Having established celiprolol as a standard of care in France for vEDS patients, we are excited to partner with Acer to help bring celiprolol to members of the U.S. patient community who are suffering from this devastating, life-threatening disease.”
expertly curated content related to this topic
-
Obstructive Sleep Apnoea and Quality of Life in Ehlers-Danlos syndrome: A Parallel Cohort StudyBACKGROUND: Patients with the connectiv...
-
Vascular Ehlers-Danlos Syndrome in Siblings with Biallelic COL3A1 Sequence Variants and Marked Clinical Variability ...Vascular Ehlers-Danlos Syndrome (vEDS), ...
-
Harry C. Dietz, III, MDDr. Harry “Hal” Dietz is a professor...
-
Holly S. Gilmer, MDDr. Gilmer is an adult and pediatric Neu...
-
Acer Therapeutics and Opexa Therapeutics Sign Merger AgreementOpexa Therapeutics, Inc. (Nasdaq: OPXA) ...
-
Michele Moscato, DODr. Moscato completed her undergraduate ...
-
Leslie Russek, PT, DPT, PhD, OCSLeslie Russek, PT, DPT, PhD, OCS, is an ...